Treating human cancer with a diabetic drug: Metformin, the widely used drug in the treatment of TIIDM, inhibits expansion of nephrogenic progenitors and wilms tumor formation by inducing its target gene, 2/May/2014, 8.19 am

Tumor suppresor AML2 suppresses the expression of autophagic modulator Beclin-1 via up regulation of it target gene, 2/May/2014, 7.34 am
May 2, 2014
Insight into the treatment of Metastatic Pancreatic/intestine/ovarian Cancer: Genistein suppresses the expression of PDGF Receptor β via up regulation of its target gene, 2/May/2014, 8.37 am
May 2, 2014
Show all

Prof. Dr. Daley GQ and co-workers from Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Children’s Hospital Boston (Harvard Medical School Teaching Hospital), Boston, Massachusetts, USA have reported recently in the prestigious journal Genes & Development. (April 14, 2014) that Lin28 sustains early renal progenitors and induces Wilms tumor. 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMDreports that:  Treating cancer with a diabetic drug: Metformin , the widely used drug in the treatment of TIIDM, inhibits expansion of nephrogenic progenitors and wilms tumor formation by inducing its target  gene.  This data may suggest that Metformin and its analogs may serve as  one of the promising therapeutic candidates in the treatment of renal cancer.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Treating human cancer with a diabetic drug: Metformin, the widely used drug in the treatment of TIIDM, inhibits expansion of nephrogenic progenitors and wilms tumor formation by inducing its target  gene, 2/May/2014, 8.19 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.